Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Modified Baitouweng decoction is a traditional Chinese medicine (TCM) formulation primarily based on the classic Baitouweng decoction, which consists of four main herbs: Pulsatilla chinensis, Coptis chinensis, Phellodendron chinense, and Fraxinus chinensis (or Fraxinus rhynchophylla)[7]. "Modified" indicates that the formulation may include additions or subtractions of herbs to tailor its effects for specific clinical indications. The decoction is mainly used for the treatment of gut-related disorders, including radiation enteritis and ulcerative colitis. Mechanistically, mBTWD is thought to exert anti-inflammatory, antioxidant, antimicrobial, and immune-modulatory effects—regulating intestinal immune function, rebalancing Th17/Treg cells, modulating the intestinal microbiota, enhancing intestinal barrier integrity, and inhibiting pro-inflammatory cytokines, possibly via pathways such as IL-6/STAT3 and FXR/TGR5 signaling[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on modified Baitouweng decoction.